Acceleron Pharma Stock Price and Value Analysis

Should you buy Acceleron Pharma stock? (NASDAQ:XLRN). Let's see how it does in our automated value investing analysis system.

  • This company has stable growth.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the XLRN Numbers

XLRN Price
(Acceleron Pharma stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 18%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,115,252 shares shorted. With 53,513,810 shares available for purchase and an average trading volume over the past 10 trading days of 1,942,554, it would take at least 1.089 days for all of the short holders to cover their shorts.

Is Acceleron Pharma Stock on Sale?

Based on our analysis, we believe that you should not buy Acceleron Pharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy XLRN Stock?

Does Acceleron Pharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.